Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged ≥2 years with Lennox-Gastaut syndrome or Dravet syndrome: A subgroup analysis of the BECOME survey
Consistent with the overall BECOME survey, most caregivers of patients with LGS/DS aged ≥2 years taking concomitant clobazam reported improvements in seizure and non-seizure outcomes since initiating CBD treatment.
Authors
- Kishan Vyas (ORCID: https://orcid.org/0000-0003-0944-9608)
- Tracy Dixon‐Salazar (ORCID: https://orcid.org/0000-0002-7801-1741)
- Timothy B. Saurer
- Michael Scott Perry (ORCID: https://orcid.org/0000-0002-1825-846X)
- Anne T. Berg (ORCID: https://orcid.org/0000-0002-0298-5523)
- Mary Anne Meskis (ORCID: https://orcid.org/0000-0003-0748-7774)
- Sherry Danese
Institutions
- Dravet Syndrome Foundation (US)
- Cook Children's Medical Center (US)
- Jazz Pharmaceuticals (United States) (US)
- Lennox-Gastaut Syndrome Foundation (US)
- Jazz Pharmaceuticals (Italy) (IT)
- Jazz Pharmaceuticals (France) (FR)
- Center for Occupational Research and Development (US)
Publication Details
- Journal
- Seizure
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1016/j.seizure.2025.04.017
- Citations
- 3
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Jazz Pharmaceuticals